[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cirrhoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cirrhoses":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,86,109,140,164,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100597412","phase-4-optimizing-portal-hypertension-with-tips-and-interval-metabolic-surgery-for-advanced-liver-disease-100597412",false,"NCT07058155","Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","OPTIMAL Trial: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","OPTIMAL","Inclusion Criteria\n\n1. Candidate for general anesthesia.\n2. Age 18-70 years at consent.\n3. BMI 35-70 kg\u002Fm² at first study visit.\n4. Eligible for sleeve gastrectomy per ASMBS\u002FIFSO 2022 guidelines.\n5. Insurance coverage for metabolic surgery.\n6. Current or prior anti-obesity medication use permitted.\n7. Liver cirrhosis confirmed by biopsy or non-invasive assessment.\n8. Clinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices \u002F portal-hypertensive gastropathy, or imaging evidence of collaterals\u002Fdilated portal vein).\n9. Able and willing to provide informed consent and comply with study procedures.\n10. Women of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years.\n\nExclusion Criteria\n\n1. Prior bariatric\u002Fmetabolic surgery (except removed devices ≥ 3 months earlier).\n2. Prior complex foregut surgery.\n3. History of solid-organ transplant.\n4. Severe pulmonary disease (FEV1 \\\u003C 50 % predicted).\n5. Significant cardiac or atherosclerotic disease with planned re-vascularization within 12 months.\n6. ASA class IV or V uncompensated cardiopulmonary disease.\n7. Left-ventricular ejection fraction \\\u003C 25 % or MI\u002Funstable angina\u002Fstroke\u002Fheart surgery\u002Fcoronary stent within 6 months.\n8. Hiatal hernia \\> 7 cm or LA grade C\u002FD erosive esophagitis.\n9. Active Crohn's disease.\n10. Severe psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol\u002Fsubstance abuse within 12 months.\n11. Pregnant, breastfeeding, planning pregnancy, or not using adequate contraception.\n12. Malignancy within the prior 12 months (except non-melanoma skin cancer).\n13. Life expectancy \\\u003C 2 years in investigator's judgment.\n14. Investigational therapy within 3 months.\n15. Acute pancreatitis ≤ 90 days.\n16. Portal vein thrombosis at screening.\n17. Decompensated cirrhosis (moderate\u002Flarge ascites, hepatic encephalopathy, or listed for liver transplant); small ascites or prior variceal bleed allowed.\n18. Total bilirubin \\> 3 mg\u002FdL, INR \\> 1.7, or platelets \\\u003C 50 000\u002FµL (within 1 month).\n19. Significant alcohol intake (\\> 14 units\u002Fweek women, \\> 21 units\u002Fweek men) within the prior 12 months.\n20. eGFR \\\u003C 45 mL\u002Fmin\u002F1.73 m² or on dialysis (within 1 month).\n21. AIDS.\n22. Unable to understand study or give consent.\n23. Plans to move more than 3 hours from Cleveland within 6 months.\n24. Previous randomization in this trial.\n25. Any condition that, in the investigator's opinion, places the subject at undue risk.","ALL","18 Years","70 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present.\n\nThis study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes.\n\nThe study will compare two groups:\n\n1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG).\n2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications).\n\nAll participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups.\n\nThe main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment.\n\nParticipants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes.\n\nThis study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.",[28,29,30,31],"Liver Cirrhoses","Portal Hypertension Related to Cirrhosis","Severe Obesity","TIPS",[33,34,35,36,37,38,39,40,41,42],"Sleeve Gastrectomy","Transjugular Intrahepatic Portosystemic Shunt (TIPS)","Bariatric Surgery \u002F Metabolic Surgery","Clinically Significant Portal Hypertension (CSPH)","Health-Related Quality of Life (HRQOL)","SF-36 Questionnaire","Weight Loss","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Randomized Controlled Trial","RECRUITING","2025-12-20",{"date":46,"type":47},"2025-12-23","ACTUAL",{"date":49,"type":47},"2025-12-17",{"date":51,"type":22},"2034-02-01",{"name":53,"class":54},"The Cleveland Clinic","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":55},"100615325","a-comparative-study-of-mri-and-ultrasound-for-detection-of-primary-hepatocellular-carcinoma-body-composition-and-risk-factors-for-decompensation-in-liver-cirrhosis-100615325","NCT07291141","A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis","DETECT-HCC","Inclusion Criteria:\n\n* Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.\n* Age ≥18 years ≤ 84\n* Written informed consent from the participant\n\nExclusion Criteria:\n\n* Contraindications for MRI (ferrrous material, claustrophobia)\n* Pregnancy\n* Diagnosis of primary sclerosing cholangitis (PSC)\n* Vascular liver disease\n* Congenital liver fibrosis\n* Previous diagnosis of hepatic carcinoma (HCC)\n* Previous liver transplant",{"count":64,"type":22},600,"OBSERVATIONAL","DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.\n\nA key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.\n\nThe protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.\n\nLongitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.\n\nThe DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.",[28,68,69,29,70,71],"Hepatocellular Carcinoma (HCC)","Sarcopenia in Liver Cirrhosis","MRI","Ultrasound",[73,74,75,76],"Abbreviated MRI","Hepatocellular carcinoma","Liver cirrhosis","Sarcopenia","2025-12-18",{"date":79,"type":47},"2025-12-19",{"date":77,"type":47},{"date":82,"type":22},"2031-12",{"name":84,"class":85},"Mattias Ekstedt","OTHER_GOV",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":55},"100339069","developing-viability-index-for-machine-perfused-livers-100339069","NCT03694691","Developing Viability Index for Machine Perfused Livers","Development of a Liver Viability Index for Transplantation","Inclusion Criteria:\n\n* Male or female 18-75 years of age.\n* Candidate for a deceased-donor liver allograft.\n\nExclusion Criteria:\n\n* Seropositivity for HIV-1.","75 Years",{"count":95,"type":22},60,[97],"NA","Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.",[28],"2025-10-31",{"date":102,"type":47},"2025-11-03",{"date":104,"type":47},"2018-10-01",{"date":106,"type":22},"2030-06-01",{"name":108,"class":54},"Massachusetts General Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":55},"100402865","liver-disease-and-other-systemic-diseases-100402865","NCT04525833","Liver Disease and Other Systemic Diseases","The Association of Liver Disease With Other Systemic Diseases, Focus on Diseases Progression, Treatments, and Clinical Outcomes: Analyses From the Hospital Database of Buddhist Tzu Chi Medical Foundation","Inclusion Criteria:\n\n* Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 99 years",true,"99 Years",{"count":119,"type":22},15000,"Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.",[122,123,124,125,126,127,128,129,28,130],"Liver Diseases","Humans","Progression","Carcinogenesis","Fatty Liver Disease","Hepatitis C","Hepatitis B","Hepatocellular Carcinoma","Treatment Outcome","2025-09-16",{"date":133,"type":47},"2025-09-19",{"date":135,"type":47},"2020-01-01",{"date":137,"type":22},"2026-12-31",{"name":139,"class":54},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":65,"phases":4,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":55},"100574186","evaluation-of-chronic-liver-disease-condition-and-transplant-prognosis-assisted-by-eye-biological-parameters-100574186","NCT06756009","Evaluation of Chronic Liver Disease Condition and Transplant Prognosis Assisted by Eye Biological Parameters","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years old;\n2. Late stage liver disease patients waiting for liver transplantation treatment, as well as patients with varying degrees of cirrhosis;\n3. Can collect complete basic demographic information, liver function blood test indicators, liver pathology and imaging examination results;\n4. Can cooperate with eye OCT, OCTA and other examinations, and obtain qualified examination parameters;\n5. Voluntarily follow the clinical trial protocol and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of other organ transplant surgeries;\n2. History of intraocular laser treatment, medication injection, and surgery;\n3. History of high myopia, glaucoma, and retinal choroidal related eye diseases;\n4. History of major systemic diseases other than liver disease;\n5. Individuals whose overall body and eye conditions cannot cooperate with eye examinations.",{"count":147,"type":22},500,"1 Year","This study investigates the correlation between ocular biological characteristics and overall conditions before and after liver transplantation by collecting ocular biological characteristics. Explore whether it is possible to construct a clinical prediction model for liver transplantation by incorporating ocular biometric features, in order to optimize disease management before and after liver transplantation.",[151,152,28],"Diagnostic Techniques, Ophthalmological","Liver Transplantation",[151,154,28],"liver transplantation","2024-12-25",{"date":157,"type":47},"2025-01-01",{"date":159,"type":47},"2022-03-01",{"date":161,"type":22},"2026-12-30",{"name":163,"class":54},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":171,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":55},"100343020","non-invasive-characterization-of-focal-liver-lesions-in-liver-cirrhosis-100343020","NCT03746210","Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis","NICETIES","Inclusion Criteria:\n\n* all patients with focal liver lesions and liver cirrhosis\n\nExclusion Criteria:\n\n* no consent\n* under 18 years",{"count":172,"type":22},200,"This study aims to analyze non-invasive characterization focal liver lesions in patients with liver cirrhosis. The diagnostic accuracy and predictive value of non-invasive methods is studied.",[28],"2022-05-17",{"date":177,"type":47},"2022-05-18",{"date":179,"type":47},"2016-01-01",{"date":181,"type":22},"2027-12-31",{"name":183,"class":54},"University Hospital, Bonn",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":55},"100373296","phase-4-antibiotic-prophylaxis-in-patients-undergoing-gvo-100373296","NCT04140578","Antibiotic Prophylaxis in Patients Undergoing GVO","Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding","ABX-GV","Inclusion Criteria:\n\n1. Patients with live cirrhosis and\u002For hepatoma\n2. Aged 20 to 85, who had endoscopy-treatment EV(-)GV(+)or EV\\\u003CGV\n\nExclusion Criteria:\n\n1. Had a terminal illness of any major organ system,such as heart failure, kindey failure,COPD\n2. Patients recieve antibiotics recently.\n3. Patients suspected infection.","20 Years","85 Years",{"count":195,"type":22},150,[25],"We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.",[199,200,28,201],"Gastric Varix","Sepsis","Fever",[203,200,204],"Gastric variceal rebleeding","cyanoacrylate injection","2019-10-24",{"date":207,"type":47},"2019-10-28",{"date":209,"type":47},"2017-01-28",{"date":211,"type":22},"2030-12-31",{"name":213,"class":85},"Taipei Veterans General Hospital, Taiwan"]